One-Year Clinical Outcomes of Subcutaneous Infliximab Maintenance Therapy Compared With Intravenous Infliximab Maintenance Therapy in Patients With Inflammatory Bowel Disease: A Prospective Cohort Study
Inflammatory Bowel Diseases · 03.04.2024 · 30 (4) · 517-528
DOI: 10.1093/ibd/izad094 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 01.06.2023. Verfasst von Sung Noh Hong und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Colitis, Ulcerative. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: National Research Foundation, Samsung Medical Center.
Abstract (Originalsprache)
Background
Although the pharmacokinetic profile of subcutaneous (SC) infliximab (IFX) is superior to conventional intravenous (IV) IFX, long-term efficacy and safety of SC IFX in patients with inflammatory bowel disease (IBD) have not been reported yet. This study aimed to evaluate long-term clinical outcomes of IBD patients treated with SC IFX compared with those of IBD patients treated with IV IFX during maintenance therapy.
Methods
This prospective cohort study enrolled 61 IBD patients in clinical remission who received scheduled IFX maintenance therapy. Of them, 38 patients were switched to SC IFX, while 23 patients continued IV IFX with dose optimization. Enrolled patients were followed up for 1 year. The primary outcome was durable remission defined as clinical remission (Crohn’s disease, Harvey-Bradshaw index <5; ulcerative colitis, partial Mayo score <2) and biochemical remission (C-reactive protein <0.5 mg/dL) with IFX trough level ≥3 µg/mL throughout the follow-up period.
Results
One-year clinical remission, 1-year biochemical remission, and mucosal healing did not differ between the IV and SC IFX groups (n = 20 of 23 vs 33 of 38; P = 1.000; n = 22 of 23 vs 34 of 38; P = .641; and n = 10 of 18 vs 17 of 25; P = .414, respectively). During follow-up, the number of patients with IFX trough level <3 μg/mL was significantly lower in the SC IFX group (n = 0 of 38, 0%) than in the IV IFX group (n = 10 of 23, 43%) (P < .001). The SC IFX group showed higher 1-year durable remission than the IV IFX group (n = 31 of 38, 82% vs n = 11 of 23, 48%; P = .013). The incidence of IFX-related adverse events did not differ significantly between both groups (26% vs 39%; P = .446).
Conclusion
The SC IFX switch induced a higher 1-year durable remission rate than continuing IV IFX in patients with IBD during scheduled maintenance therapy, showing similar safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
ORCID-Profile: Sung Noh Hong, Young-Ho Kim
Förderung
- National Research Foundation
- Samsung Medical Center
Zitieren
APA
Hong, S. N., Hye Song, J., Jin Kim, S., Ha Park, Y., Wan Choi, C., Eun Kim, J., Ran Kim, E., Kyung Chang, D., & Kim, Y. H. (2024). One-Year Clinical Outcomes of Subcutaneous Infliximab Maintenance Therapy Compared With Intravenous Infliximab Maintenance Therapy in Patients With Inflammatory Bowel Disease: A Prospective Cohort Study. Inflammatory Bowel Diseases, 30(4), 517-528. https://doi.org/10.1093/ibd/izad094
Vancouver
Hong SN, Hye Song J, Jin Kim S, Ha Park Y, Wan Choi C, Eun Kim J, et al. One-Year Clinical Outcomes of Subcutaneous Infliximab Maintenance Therapy Compared With Intravenous Infliximab Maintenance Therapy in Patients With Inflammatory Bowel Disease: A Prospective Cohort Study. Inflammatory Bowel Diseases. 2024;30(4):517-528. doi:10.1093/ibd/izad094
BibTeX
@article{Hong2024,
author = {Hong, Sung Noh and Hye Song, Joo and Jin Kim, Sung and Ha Park, Yoon and Wan Choi, Chang and Eun Kim, Ji and Ran Kim, Eun and Kyung Chang, Dong and Kim, Young-Ho},
title = {One-Year Clinical Outcomes of Subcutaneous Infliximab Maintenance Therapy Compared With Intravenous Infliximab Maintenance Therapy in Patients With Inflammatory Bowel Disease: A Prospective Cohort Study},
journal = {Inflammatory Bowel Diseases},
year = {2024},
volume = {30},
number = {4},
pages = {517--528},
doi = {10.1093/ibd/izad094}
}
EUVIMED